Cargo Therapeutics, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
CARGO Therapeutics, Inc. has completed its acquisition by Concentra Biosciences, LLC, with shareholders receiving $4.379 cash and a contingent value right per share.
8-K: CARGO Therapeutics to be Acquired by Concentra Biosciences in Cash and Contingent Value Rights Deal
CARGO Therapeutics, Inc. has entered into a definitive merger agreement to be acquired by Concentra Biosciences, LLC for $4.379 per share in cash plus a contingent value right.
CARGO Therapeutics, Inc. has assigned its San Carlos, California lease, incurring a $36.3 million cash payment, as it continues to suspend development efforts and explore strategic alternatives.
CARGO Therapeutics, Inc. announced the successful election of three Class II directors and the ratification of Deloitte & Touche LLP as its independent auditor at its 2025 Annual Meeting of Stockholders.
CARGO Therapeutics suspends pipeline development, reduces workforce by 90%, appoints interim CEO, and explores strategic options including a potential reverse merger.
CARGO Therapeutics presents a corporate update highlighting its allogeneic vector platform designed to overcome limitations in cell therapy and the progress of its CRG-023 program targeting B-cell malignancies.
CARGO Therapeutics discontinues its FIRCE-1 Phase 2 study, reduces workforce by 50%, and expects to extend its cash runway to mid-2028.
CARGO Therapeutics provides a corporate update, including anticipated milestones for 2025, progress on its clinical programs, and an estimated cash balance of $368.1 million as of December 31, 2024.
CARGO Therapeutics announced its third quarter 2024 financial results, highlighted by progress in its Phase 2 clinical study of firi-cel and advancements in its CRG-023 program.
CARGO Therapeutics announced its second quarter 2024 financial results, highlighted by the completion of a $110 million private placement and progress in its Phase 2 clinical study for firi-cel.
CARGO Therapeutics has entered into a sublease agreement with Vaxcyte for a portion of its headquarters, aiming to optimize the use of its office space.
CARGO Therapeutics has increased its board size, appointed Jane Pritchett Henderson as a new director, and announced the results of its 2024 Annual Meeting of Stockholders.
CARGO Therapeutics has entered into a securities purchase agreement for a $110 million private placement of common stock with healthcare-focused institutional investors.
CARGO Therapeutics announced its first quarter 2024 financial results and provided a business update, highlighting progress in its Phase 2 clinical study for firi-cel and advancements in its preclinical pipeline.
CARGO Therapeutics has appointed Kapil Dhingra to its Board of Directors, increasing the board size from six to seven members.
CARGO Therapeutics announced its 2023 financial results and provided an update on its clinical programs, including the ongoing Phase 2 trial of firi-cel.
Cargo Therapeutics has amended its license and supply agreement with Oxford Biomedica, altering royalty payments and milestone structures for its lentiviral vector technology.